Biblio
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol. 2015;2(8):e339-46.
.
Treatment Recommendations for Chronic Myeloid Leukemia. Mediterr J Hematol Infect Dis. 2014;6(1):e2014005.
.